natgillin/translations-raw huggingface dataset:
give dig anden medicin for at forebygge komplikationer og mildne dine symptomer, udsætte den næste dosis Nivolumab BMS, eller helt stoppe din behandling med Nivolumab BMS.
give you other medicines in order to prevent complications and reduce your symptoms, withhold the next dose of Nivolumab BMS, or stop your treatment with Nivolumab BMS altogether.
give dig anden medicin for at forebygge komplikationer og mildne dine symptomer, udsætte den næste dosis OPDIVO, eller helt stoppe din behandling med OPDIVO.
give you other medicines in order to prevent complications and reduce your symptoms, withhold the next dose of OPDIVO, or stop your treatment with OPDIVO altogether.
give hjertearytmier.
imeprevir are expected.
Give oplysninger om bivirkninger
Provides information on the possible side effects
Give oplysninger om, hvordan Truvada opbevares.
Provides information on how to store Truvada.
Give oplysninger om, hvordan Truvada tages
Provides information on how to take Truvada
give samme eksponering som
provide exposure similar to a
Give sikkerhedsoplysninger om adhærens, HIV-testning samt nyre-, knogle- og HBV-status.
Provides safety information on adherence, HIV testing, renal, bone and HBV status.
Give udførlig vejledning og rådgivning til patienterne.
The need to provide comprehensive advice and counselling to patients.
givelsessyndr om4,
cranial
Giver 0,75 mg/ml ved fortynding som anbefalet
Provides 0.75 mg/ml when diluted as recommended
giver oplysninger om antallet af klargøringspump
gives instruction on number of priming strokes
gives digoxin til patienter i
digoxin is given to patients on
Gives opblandet i foder eller direkte i munden.
To be administered with food or directly into the mouth.
gives sammen med PREZISTA og
A safe and effective dose of
gives telaprevir 1,125 mg hver 8.
every 8 hours)
Gives yderligere en dosis, skal denne gives mindst 3 uger efter den første dosis.
If a second dose is administered there should be an interval of at least three weeks between the first and second dose.
Gives yderligere en dosis, skal denne gives mindst tre uger efter den første dosis.
If a second dose is administered there should be an interval of at least three weeks between the first and second dose.
Gives yderligere en dosis, skal der være et interval på mindst 3 uger mellem første og anden dosis.
If a second dose is administered there should be an interval of at least three weeks between the first and the second dose.
Givet det lille antal af andre racer inkluderet i de kliniske studier, kan der ikke drages konklusioner om effekten af UTG1A9 hos andre etniske grupper.
Due to the low number of other races included in the clinical studies, no conclusions can be drawn on the effect of UTG1A9 in other ethnic groups.
Givet dets toksiske beskaffenhed bør der tages specielle forholdsregler ved håndteringen af DepoCyte.
Given its toxic nature, special precautions should be taken in handling DepoCyte.
givet over 2 – 5 dage
given over 2-5 days
givet over 2-5 dage
given over 2-5 days
GIVET SAMMEN MED
when co-administered with
givet som fast
(as given in a
GLA-mutationerne er endvidere tilgængelige for sundhedspersoner på www.galafoldamenabilitytable.com.
The GLA mutations are also accessible by health care providers at www.galafoldamenabilitytable.com:
Glanzmanns trombasteni
Glanzmann’s thrombasthenia
Glas
BOTTLE
Glas
Glass vial
Glas
Naxcel
Glas (30 ml)
Bottle (30 ml)
Glas (40 ml)
Bottle (40 ml)
Glas (60 ml)
Bottle (60 ml)
glas (HDPE)
bottle (HDPE)
Glas hætteglas
Glass vial
Glas hætteglas: 20 ml hætteglas, glas type I
Glass vials: 20 ml vials, glass type I
GLAS MED PULVER 500 IE GLAS MED PULVER 1000 IE
VIAL OF POWDER 500 IU VIAL OF POWDER 1000 IU
GLAS MED SOLVENS 5 ml GLAS MED SOLVENS 10 ml
VIAL OF SOLVENT 5 ml VIAL OF SOLVENT 10 ml
Glas type I
Glass type I
Glas à 30 tabletter Glas à 90 tabletter
Bottle of 30 tablets Bottle of 90 tablets
Glas-hætteflaske med gummistop og aluminiumshætte
Glass vial with rubber stopper and aluminium cap
Glas-hætteflaske med lukket gummistop og aluminiumshætte
Glass vial closed rubber stopper and aluminium cap
Glasampul af Type I borsilikat, 10 ml.
Type I borosilicate glass ampoule of 10 ml.
GLASBOKS MED PULVER 500 IE GLASBOKS MED PULVER 1000 IE
BOX VIAL OF POWDER 500 IU BOX VIAL OF POWDER 1000 IU
GLASETIKET
BOTTLE LABEL
Glasetiket
Label
GLASFLASKE
GLASS BOTTLE
Glasflaske Glasflaske
actuation
Glasflaske med 120 ml propranolol i oral opløsning
The glass bottle containing 120 mL propranolol oral solution
Glasflasken med 150 ml Keppra (til spædbørn fra 1 måned til under 6 måneder) er pakket i en æske, der indeholder en 1 ml oral doseringssprøjte (med en målestreg for hver 0,05 ml) samt en adapter til sp røjten.
The 150 ml glass bottle of Keppra (for infants aged 1 month to less than 6 months) is packed in a cardboard box containing a 1 ml oral syringe (graduated every 0.05 ml) and an adaptor for the syringe.
Glasflasken med 300 ml Keppra (til børn fra 4 år og op efter, unge og voksne) er p akket i en æske, der indeholder en 10 ml oral doseringssprøjte (med en målestreg for hver 0,25 ml) samt en adapter til sp røjten.
The 300 ml glass bottle of Keppra (for children aged 4 years and above, adolescents and adults) is packed in a cardboard box containing a 10 ml oral syringe (graduated every 0.25 ml) and an adaptor for the syringe.
Glaslegemeblødning*
Vitreous haemorrhage
Glaspakningen indeholder beholdere med et tørremiddel for at holde tabletterne tørre.
The bottle pack contains canisters with a desiccant for keeping the tablets dry.
Glasset er et plastikglas af højdensitetspolyethylen (HDPE), som indeholder 120 tabletter og tre poser med tørremiddel og er forsynet med et børnesikret låg af polypropylen (PP).
The bottle is a high-density polyethylene (HDPE) plastic bottle containing 120 tablets and 2 desiccant pouches, fitted with a polypropylene (PP) child resistant closure.
Glasset er et plastikglas af højdensitetspolyethylen (HDPE), som indeholder 120 tabletter og tre poser med tørremiddel og er forsynet med et børnesikret låg af polypropylen (PP).
The bottle is a high-density polyethylene (HDPE) plastic bottle containing 120 tablets and 3 desiccant pouches, fitted with a polypropylene (PP) child resistant closure.
Glasset er et plastikglas af højdensitetspolyethylen (HDPE), som indeholder 60 tabletter og tre poser med tørremiddel og er forsynet med et børnesikret låg af polypropylen (PP).
The bottle is a high-density polyethylene (HDPE) plastic bottle containing 60 tablets and 3 desiccant pouches, fitted with a polypropylene (PP) child resistant closure.
Glasset er forsynet med et børnesikret låg, der fjernes på følgende måde:
The plastic bottle comes with a child resistant cap and should be opened as follows:
Glasset indeholder to små poser med tørremiddel, som holder tabletterne tørre.
The bottle contains 2 little pouches (desiccants) to keep the tablets dry.
Glasset indeholder tre små poser med tørremiddel, som holder tabletterne tørre.
The bottle contains 3 little pouches (desiccants) to keep the tablets dry.
Glassets etiket - 10 ml, 20 ml og 60 ml glas
Bottle label – 10 ml, 20 ml and 60 ml bottles
Glat, let gullig salve.
Smooth, off-white ointment.
Glatiramer
(0.52, 1.14)
glaukom (øget tryk i øjet), problemer med øjenbevægelse, rullende øjne, øget følsomhed i øjnene over for lys, øget tåreproduktion, røde øjne
glaucoma (increased pressure within the eyeball), problems with movement of your eyes, eye rolling, oversensitivity of the eyes to light, increased tears, redness of the eyes
glaukom (øget tryk i øjet), problemer med øjenbevægelse, rullende øjne.
glaucoma (increased pressure within the eyeball), problems with movement of your eyes, eye rolling
glaukom (øget tryk i øjet), øget tåreproduktion, røde øjne, problemer med øjenbevægelse, rullende øjne
glaucoma (increased pressure within the eyeball), increased tears, redness of the eyes, problems with movement of your eyes, eye rolling
Glaukom, forstyrrede øjenbevægelserc, øjenrulningc, øget
gamma-glutamyltransf erase increased, hepatic enzyme
glaukom;
glaucoma;
Glaxo Group Limited 980 Great West Road Brentford
Glaxo Group Ltd 980 Great West Road Brentford
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, Storbritannien.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Storbritannien.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
Glaxo Group Limited.
Glaxo Group Limited
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, Storbritannien
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Storbritannien
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Storbritannien Fremstiller:
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom Manufacturer:
Glaxo Group Ltd, Greenford, Middlesex, UB6 0NN, Storbritannien
Glaxo Group Ltd, Greenford, Middlesex, UB6 0NN, United Kingdom
Glaxo Operations UK Limited (Forhandler som Glaxo Wellcome Operations)
Glaxo Operations UK Limited (Trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Limited (Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Limited (registreret som Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations)
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations): Harmire Road, Barnard Castle, County Durham DL12 8DT, Storbritannien.
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations): Harmire Road, Barnard Castle, County Durham DL12 8DT, United Kingdom.
Glaxo Operations UK Limited (under forretningsnavnet Glaxo Wellcome Operations)
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations)
Glaxo Operations UK Limited (under forretningsnavnet Glaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12 8DT, Storbritannien.
Glaxo Operations UK Limited (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12 8DT, United Kingdom.
Glaxo Operations UK Limited, der driver virksomhed under navnet Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, UK.
Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, United Kingdom
Glaxo Operations UK Ltd (Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK, Ltd,(trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Oparations), Priory Street, Ware, Hertfordshire, SG 12 0DJ, Storbritannien.
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG 12 0DJ, United Kingdom.
Glaxo Operations UK Ltd.
Glaxo Operations UK Ltd
Glaxo Operations UK Ltd. (registreret som GlaxoWellcome Operations)
Glaxo Operations UK Ltd
Glaxo Wellcome Farmacêutica, Lda Tel: + 351 21 412 95 00
Tel: + 351 21 412 95 00
Glaxo Wellcome Operations, Priory Street, Ware, Hertfordshire SG12 0DJ, Storbritannien.
Glaxo Wellcome Operations, Priory Street, Ware, Hertfordshire SG12 0DJ, United Kingdom
Glaxo Wellcome Production, 1, rue de l’Abbaye, F-76960 Notre Dame de Bondeville, Frankrig
Glaxo Wellcome Production, 1 rue de l'Abbaye, F-76960 Notre Dame de Bondeville, France.
Glaxo Wellcome S.A Avenida de Extremadura 3 09400 Aranda de Duero Burgos
Glaxo Wellcome S.A. Avenida de Extremadura 3 09400 Aranda de Duero Burgos
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero Burgos, Spanien.
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero Burgos, Spain.
GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 4955000
GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 495 5000
GlaxoSmithKline A.E.B.E. Τηλ: + 30 210 68 82 100
Τηλ: + 30 210 68 82 100
GlaxoSmithKline Biologicals Kft.
GlaxoSmithKine Biologicals Kft.
GlaxoSmithKline Biologicals S.A 89 rue de I’institut-1330 Rixensart Belgien
GlaxoSmithKline Biologicals S.A. 89 rue de I’Institut-1330 Rixensart Belgium
GlaxoSmithKline Biologicals S.A. 89, rue de l’Institut - 1330 Rixensart Belgien
GlaxoSmithKline Biologicals S.A. 89, rue de l’Institut – 1330 Rixensart Belgium
GlaxoSmithKline Biologicals SA Parc de la Noire Epine rue Flemming 20-1300 Wavre Belgien
GlaxoSmithKline Biologicals SA Parc de la Noire Epine rue Flemming 20-1300 Wavre Belgium
GlaxoSmithKline Consumer Healthcare Tel: + 44 (0)800 171 2014(Freephone) customer.relations@gsk.com
GlaxoSmithKline Consumer Healthcare Tel: + 44 (0)800 171 2014 (Freephone) customer.relations@gsk.com
GlaxoSmithKline d.o.o.
GSK d.o.o., Ljubljana
GlaxoSmithKline LLC 893 River Road Conshohocen, PA19428
893 River Road Conshohocken, PA 19428
GlaxoSmithKline Malta (Malta) Limited Tel: + 356 21 238131
Nederland GlaxoSmithKline BV Tel: + 31 (0)30 6938100 nlinfo@gsk.com
GlaxoSmithKline Manufacturing S.p.A Strada Provinciale Asolana 90
GlaxoSmithKline Manufacturing S.p.A. Strada Provinciale Asolana 90
GlaxoSmithKline Manufacturing S.P.A. Strada Provinciale Asolana N.90, Torrile, 43056
Strada Provinciale Asolana N. 90, Torrile, 43056,
GlaxoSmithKline Manufacturing S.p.A. Via Alessandro Fleming 2
GlaxoSmithKline Manufacturing S.p.A. Via Alessandro Fleming 2 Verona 37135
GlaxoSmithKline Pharmaceuticals S.A ul.
GlaxoSmithKline Pharmaceuticals S.A. ul.
GlaxoSmithKline Pharmaceuticals S.A. Tel.: + 48 (0)22 576 9000
Tel.: + 48 (0)22 576 9000
Glemmer at injicere dit insulin eller stopper med at tage insulin
Forget to inject your insulin or stop taking insulin.
Glemmer at injicere dit insulin eller stopper med at tage insulin.
Forget to inject your insulin or stop taking insulin.
Glemmer at tage dit insulin eller stopper med at tage dit insulin.
Forget to take your insulin or stop taking insulin.
Glemmer at tage insulin eller stopper med at tage insulin.
Forget to take your insulin or stop taking insulin.
glemsomhed
forgetfulness
Glemsomhed, forvirring, krampeanfald, usammenhængende tale, rysten (tremor)
forgetfulness, confusion, fitting (seizures), incoherent speech, tremor (shaking)
Glemsomhed, irritabilitet, forvirring, nervøsitet
Feeling forgetful, irritable, confused, nervous
Glemt dosis (primær forebyggelse af VTE ved ortopædkirurgi)
Missed dose (pVTEp orthopaedic surgery)
Glemt dosis (SPAF, DVT/LE)
Missed dose (SPAF, DVT/PE)
Glemt dosis/glemte doser
Missed dose (s)
Glemte gule placebo-tabletter
Yellow placebo tablets missed
Glemte gule placebo-tabletter‌
Yellow placebo tablets missed
Glenmark Pharmaceuticals Europe Limited Laxmi House, 2-B Draycott Avenue, Kenton, Harrow, Middlesex, HA3 OBU, Storbritannien
Glenmark Pharmaceuticals Europe Limited Laxmi House, 2-B Draycott Avenue, Kenton, Harrow, Middlesex, HA3 OBU, United Kingdom
Glenmark Pharmaceuticals Europe Limited Tél/Tel: + (0)800 4580 383
Glenmark Pharmaceuticals Europe Limited Tél/Tel: + 44 (0)800 4580 383
Glenmark Pharmaceuticals Europe Limited Tél/Tel: + 44 (0)1707 630900
Glenmark Pharmaceuticals Europe Limited Tél/Tel: + 44 (0)800 4580 383
glibenclamid, metformin, repaglinid – anvendes til behandling af sukkersyge
glibenclamide, metformin, repaglinide – used to treat diabetes
Glibenclamid: Samtidig administration af bosentan 125 mg to gange dagligt i 5 dage reducerede plasmakoncentrationen af glibenclamid (et CYP3A4-substrat) med 40% med potentiel betydelig reduktion af den hypoglykæmiske virkning.
Glibenclamide: co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma concentrations of glibenclamide (a CYP3A4 substrate) by 40%, with potential significant decrease of the hypoglycaemic effect.
Glidipion 15 mg pioglitazon
Glidipion 30 mg tablets pioglitazone
Glidipion 15 mg tabletter er hvide, runde, flade, skråkantede, 5,5 mm i diameter og mærket med ”TZ15” på den ene side.
Glidipion 15 mg tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved with ‘TZ15’ on one side.
Glidipion 15 mg tabletter Glidipion 30 mg tabletter Glidipion 45 mg tabletter
Glidipion 15 mg tablets Glidipion 30 mg tablets Glidipion 45 mg tablets
Glidipion 15 mg tabletter pioglitazon
Glidipion 15 mg tablets pioglitazone
Glidipion 15 mg, 30 mg og 45 mg tabletter Glidipion 15 mg tabletter Glidipion 30 mg tabletter Glidipion 45 mg tabletter
Glidipion 15 mg, 30 mg and 45 mg tablets Glidipion 15 mg tablets Glidipion 30 mg tablets Glidipion 45 mg tablets
Glidipion 30 mg tabletter er hvide, runde, flade, skråkantede, 7 mm i diameter og mærket med ”TZ30” på den ene side.
Glidipion 30 mg tablets are white, round, flat, bevelled, 7 mm in diameter and engraved with ‘TZ30’ on one side.
Glidipion 45 mg pioglitazon
Glidipion 45 mg tablets pioglitazone
Glidipion 45 mg tabletter er hvide, runde, flade, skråkantede, 8 mm i diameter og mærket med ”TZ45” på den ene side.
Glidipion 45 mg tablets are white, round, flat, bevelled, 8 mm in diameter and engraved with ‘TZ45’ on one side.
Glidipion er et “generisk lægemiddel”.
Glidipion is a ‘generic medicine’.
Glidipion kan desuden anvendes sammen med både metformin og et sulfonylurinstof til patienter, som ikke er tilfredsstillende reguleret trods dobbelt terapi med orale lægemidler (“tredobbelt terapi”).
Glidipion can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy’).
Glidipion kan også anvendes i kombination med metformin til patienter, som ikke er tilfredsstillende reguleret med metformin alene, eller sammen med et sulfonylurinstof (en anden type lægemiddel mod diabetes), hvor metformin ikke er egnet (“dobbelt terapi”).
Glidipion can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy’).
glimepirid (N=132)
glimepiride (N=132)
Glimepirid 4 mg/dag
Glimepiride 4 mg/day
Glimepirid 8 mg/day
Glimepiride 8 mg/day
Glimepirid AUC0–t, AUC0-inf og Cmax blev i gennemsnit forøget med henholdsvis 30 %, 19 % og 55 %.
Glimepiride AUC0-t, AUC0-inf and Cmax were increased by 30%, 19% and 55% respectively, on average.
Glimepirid har været på markedet i EU siden 1995.
Glimepiride has been available in the EU since 1995.
Glimepirid hæmmer leverens glukosedannelse ved at øge den intracellulære koncentration af fruktose-2,6- biphosphat, som hæmmer glukoneogenesen.
Glimepiride inhibits the hepatic glucose production by increasing the intracellular concentration of fructose-2,6 bisphosphate, which in turn inhibits gluconeogenesis.
Glimepirid hæmmer leverens glukosedannelse ved at øge intracellulær koncentration affruktose- 2,6-biphosphat, som igen hæmmer glukoneogenesen.
Glimepiride inhibits the glucose production in the liver by increasing the intracellular concentration of fructose-2,6-bisphosphate, which in turn inhibits the gluconeogenesis.
Glimepirid passerer kun blod- hjernebarrieren i ringe grad.
Passage of the blood brain barrier is low.
Glimepirid virker hovedsageligt ved at stimulere insulinfrigivelsen fra -cellerne i pankreas.
Glimepiride acts mainly by stimulating the release of insulin from the beta cells of the pancreas.
Glimepirids virkning er dosisafhængig og reproducerbar.
The effect of glimepiride is dose- dependent and reproducible.
Gliolan 30 mg/ml pulver til oral opløsning
Gliolan 30 mg/ml powder for oral solution
Gliolan er indiceret til voksne patienter til visualisering af malignt væv under kirurgisk indgreb for malignt gliom (WHO-grad III og IV).
Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV).
Gliolan fås i pakninger med 1, 2 og 10 hætteglas.
Gliolan is provided in a glass vial and presented in packs of 1, 2 and 10 vials.
Gliolan må kun anvendes af neurokirurger, som har deltaget i et uddannelsesforløb i henhold til nedenstående standarder:
Gliolan should be used only by neurosurgeons who have attended a training course in accordance with the standards detailed below:
Glipizid
Glipizide
Glivec (imatinib) 400 mg 1 gang dagligt n=283 (%)
Glivec (imatinib) 400 mg once daily n=283 (%)
Glivec 100 mg filmovertrukne tabletter er meget mørkegule til brun-orange runde tabletter.
Glivec 100 mg film-coated tablets are very dark yellow to brownish-orange round tablets.
Glivec 100 mg filmovertrukne tabletter Imatinib
Glivec 100 mg film-coated tablets Imatinib
Glivec 100 mg hårde kapsler Imatinib
Glivec 100 mg hard capsules Imatinib
Glivec 100 mg kapsler er orange til orange-grålig og præget med ”NVR SI”.
Glivec 100 mg capsules are orange to greyish-orange and marked “NVR SI”.
Glivec 100 mg kapsler Imatinib
Glivec 100 mg capsules Imatinib
Glivec 100 mg tabletter Imatinib
Glivec 100 mg tablets Imatinib
Glivec 400 mg filmovertrukne tabletter er meget mørkegule til brun-orange ovale tabletter.
Glivec 400 mg film-coated tablets are very dark yellow to brownish-orange oval tablets.
Glivec 400 mg filmovertrukne tabletter Imatinib
Glivec 400 mg film-coated tablets Imatinib
Glivec 400 mg tabletter Imatinib
Glivec 400 mg tablets Imatinib
Glivec 50 mg hårde kapsler
Glivec 50 mg hard capsules
Glivec 50 mg hårde kapsler Imatinib
Glivec 50 mg hard capsules Imatinib
Glivec 50 mg kapsler er lysegule til orange-gule og præget med ”NVR SH”.
Glivec 50 mg capsules are light yellow to orange-yellow and marked “NVR SH”.
Glivec 50 mg kapsler Imatinib
Glivec 50 mg capsules Imatinib
Glivec anbefales ikke under graviditeten, medmindre det er strengt nødvendigt, da det kan skade din baby.
Glivec is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Glivec anvendes til behandling af voksne med GIST, som ikke kan fjernes kirurgisk, eller som har spredt sig til andre dele af kroppen, og til voksne, hvor der er risiko for et tilbagefald af GIST efter operativ fjernelse dermatofibrosarcoma protuberans (DFSP), en form for kræft (sarkom), hvor cellerne i vævet under huden begynder at dele sig ukontrolleret.
Glivec is used to treat adults with GIST that cannot be removed with surgery or have spread to other parts of the body, and adults who are at risk of GIST coming back after surgical removal; dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Glivec anvendes, når patienten er ‘Philadelphia-kromosom-positiv’ (Ph+).
Glivec is used when the patients are ‘Philadelphia chromosome positive’ (Ph+).
Glivec blev administreret periodisk i kohorte 1-5 med stigende varighed og tidligere start med Glivec fra kohorte til kohorte; kohorte 1 fik den mindst intensive Glivec- behandling og kohorte 5 den mest intensive (længste varighed i dage med kontinuerlig, daglig Glivec- dosering i de første kemobehandlingsforløb).
Glivec was administered intermittently in cohorts 1-5, with increasing duration and earlier start of Glivec from cohort to cohort; cohort 1 receiving the lowest intensitiy and cohort 5 receiving the highest intensity of Glivec (longest duration in days with continuous daily Glivec dosing during the first chemotherapy treatment courses).